Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment

BACKGROUND: Approximately 30% of patients with the systemic autoimmune/inflammatory disorder systemic lupus erythematosus (SLE) develop lupus nephritis (LN) that affects treatment and prognosis. Easily accessible biomarkers do not exist to reliably predict renal disease. The Maximizing SLE Therapeut...

Descripción completa

Detalles Bibliográficos
Autores principales: Davies, Jennifer C, Midgley, Angela, Carlsson, Emil, Donohue, Sean, Bruce, Ian N, Beresford, Michael W, Hedrich, Christian M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Lupus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722276/
https://www.ncbi.nlm.nih.gov/pubmed/32723832
http://dx.doi.org/10.1136/rmdopen-2020-001257

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722276/
https://www.ncbi.nlm.nih.gov/pubmed/32723832
http://dx.doi.org/10.1136/rmdopen-2020-001257

Ejemplares similares